ABVX SEC filings (2026)
CIK 1956827 · Pharmaceutical Preparations (SIC 2834) · incorporated in I0 · fiscal year ends in December
105 filings on EDGAR since 2022 · 3 annual, 0 quarterly, 36 current · financial statements · earnings
What happened, last 12 months#
Every earnings release with its print, every report with its quarter, the other 8-Ks by the headline of the press release they furnish or by their items, the proxy statements, and each day an insider bought or sold — newest first, each line opening the filing on EDGAR. The index by form and year follows.
September 2026
- Sep 218-K8-K · Report of a foreign private issuer
July 2026
- Jul 28-K8-K · Report of a foreign private issuer
June 2026
- Jun 298-K8-K · Report of a foreign private issuer
- Jun 28-K8-K · Report of a foreign private issuer
May 2026
- May 228-K8-K · Report of a foreign private issuer
- May 208-K8-K · Report of a foreign private issuer
- May 78-K8-K · Report of a foreign private issuer
April 2026
- Apr 208-K8-K · Report of a foreign private issuer
March 2026
February 2026
- Feb 238-K8-K · Report of a foreign private issuer
December 2025
- Dec 158-K8-K · Report of a foreign private issuer
Insider transactions#
What officers, directors and 10% holders reported on Forms 4 and 5 over the last 13 months, from the documents themselves: one insider’s trades of one kind on one day are one row, with the shares, the price range and the total as filed. Open-market buys and sells first; awards, exercises, tax withholding, gifts and employee-plan purchases are grouped below them.
No Form 4 transaction on file for ABVX in the window. Transaction details are read from the documents filed since January 2026; the filings themselves are counted below.
Reports and proxy statements#
Annual reports (10-K, 20-F, 40-F), quarterly reports (10-Q), current reports (8-K, 6-K) and proxy statements, newest first. An 8-K that furnishes a press release is headed by the release’s headline, its items beneath; any other 8-K is described by its items. A form opens the press release where there is one, else the document on EDGAR, or the filing’s index where it furnishes other exhibits.
2026 · 11 filings
| Filed | What it is |
|---|---|
| Sep 21, 20266-K | Report of a foreign private issuer |
| Jul 2, 20266-K | Report of a foreign private issuer |
| Jun 29, 20266-K | Report of a foreign private issuer |
| Jun 2, 20266-K | Report of a foreign private issuer |
| May 22, 20266-K | Report of a foreign private issuer |
| May 20, 20266-K | Report of a foreign private issuer |
| May 7, 20266-K | Report of a foreign private issuer |
| Apr 20, 20266-K | Report of a foreign private issuer |
| Mar 23, 202620-F | Annual report (foreign private issuer), FY2025 — net income −$380.3M, EPS −$5.47 |
| Mar 23, 20266-K | Report of a foreign private issuer |
| Feb 23, 20266-K | Report of a foreign private issuer |
2025 · 11 filings
| Filed | What it is |
|---|---|
| Dec 15, 20256-K | Report of a foreign private issuer |
| Sep 8, 20256-K | Report of a foreign private issuer |
| Jul 24, 20256-K | Report of a foreign private issuer |
| Jul 22, 20256-K | Report of a foreign private issuer |
| Jun 11, 20256-K | Report of a foreign private issuer |
| Jun 2, 20256-K | Report of a foreign private issuer |
| Apr 29, 20256-K | Report of a foreign private issuer |
| Apr 22, 20256-K | Report of a foreign private issuer |
| Mar 24, 202520-F | Annual report (foreign private issuer), FY2024 — net income −$190.6M, EPS −$3.03 |
| Mar 24, 20256-K | Report of a foreign private issuer |
| Jan 10, 20256-K | Report of a foreign private issuer |
2024 · 17 filings
| Filed | What it is |
|---|---|
| Dec 23, 20246-K | Report of a foreign private issuer |
| Nov 19, 20246-K | Report of a foreign private issuer |
| Nov 14, 20246-K | Report of a foreign private issuer |
| Oct 3, 20246-K | Report of a foreign private issuer |
| Oct 3, 20246-K | Report of a foreign private issuer |
| Sep 26, 20246-K | Report of a foreign private issuer |
| Sep 25, 20246-K | Report of a foreign private issuer |
| Sep 9, 20246-K | Report of a foreign private issuer |
| Sep 9, 20246-K | Report of a foreign private issuer |
| Aug 6, 20246-K | Report of a foreign private issuer |
| Jul 16, 20246-K | Report of a foreign private issuer |
| Jun 4, 20246-K | Report of a foreign private issuer |
| May 7, 20246-K | Report of a foreign private issuer |
| Apr 5, 202420-F | Annual report (foreign private issuer), FY2023 — net income −$159.8M, EPS −$3.71 |
| Apr 2, 20246-K | Report of a foreign private issuer |
| Feb 2, 20246-K | Report of a foreign private issuer |
| Jan 22, 20246-K | Report of a foreign private issuer |
Insider, ownership and other filings#
Insider ownership (Forms 3, 4, 5 and 144), beneficial ownership (Schedules 13D and 13G), registration and prospectus (S-1, S-3, S-8, 424B and related) and the rest, counted by year, with the newest 25 of each of the latest 3 years shown. A Form 4 is one insider’s transaction report; a 13G is a passive holder above five percent.
2026 · 15 filings — 3 × SCHEDULE 13D/A, 3 × SCHEDULE 13G/A, 2 × 424B5 and 6 other forms
| Filed | What it is |
|---|---|
| Sep 21, 2026F-6EF | Other filings |
| Aug 14, 2026SCHEDULE 13G/A | Other filings |
| Aug 13, 2026SCHEDULE 13G/A | Other filings |
| Jul 6, 2026SCHEDULE 13D/A | Other filings |
| Jul 2, 2026424B5 | Prospectus supplement |
| Jul 1, 2026FWP | Free writing prospectus |
| Jun 30, 2026FWP | Free writing prospectus |
| Jun 30, 2026424B5 | Prospectus supplement |
| Jun 30, 2026POSASR | Registration and prospectus |
| May 11, 2026SCHEDULE 13D/A | Other filings |
| May 7, 2026424B7 | Registration and prospectus |
| Mar 23, 2026S-8 | Employee stock plan registration |
| Feb 13, 2026SCHEDULE 13G/A | Other filings |
| Jan 14, 2026SCHEDULE 13D/A | Other filings |
| Jan 8, 2026144 | Notice of proposed sale (Form 144) |
2025 · 14 filings — 3 × SCHEDULE 13D/A, 3 × SCHEDULE 13G/A, 2 × 424B5 and 5 other forms
| Filed | What it is |
|---|---|
| Nov 14, 2025SCHEDULE 13G/A | Other filings |
| Nov 14, 2025SCHEDULE 13G/A | Other filings |
| Oct 30, 2025SCHEDULE 13D/A | Other filings |
| Oct 28, 2025144 | Notice of proposed sale (Form 144) |
| Aug 14, 2025SCHEDULE 13G/A | Other filings |
| Jul 31, 2025SCHEDULE 13D/A | Other filings |
| Jul 24, 2025424B5 | Prospectus supplement |
| Jul 24, 2025FWP | Free writing prospectus |
| Jul 23, 2025FWP | Free writing prospectus |
| Jul 23, 2025424B5 | Prospectus supplement |
| Jul 23, 2025F-3ASR | Registration and prospectus |
| Apr 11, 2025SCHEDULE 13G | Other filings |
| Mar 24, 2025S-8 | Employee stock plan registration |
| Feb 14, 2025SCHEDULE 13D/A | Other filings |
2024 · 7 filings — 2 × SC 13G/A, 1 × CORRESP, 1 × EFFECT and 3 other forms
| Filed | What it is |
|---|---|
| Nov 26, 2024EFFECT | Other filings |
| Nov 25, 2024CORRESP | Letter to the SEC |
| Nov 22, 2024UPLOAD | Letter from the SEC staff |
| Nov 19, 2024F-3 | Registration and prospectus |
| Nov 14, 2024SC 13G/A | Passive holder above 5% (Schedule 13G), amended |
| Apr 19, 2024SC 13G | Passive holder above 5% (Schedule 13G) |
| Feb 14, 2024SC 13G/A | Passive holder above 5% (Schedule 13G), amended |
2023 · 29 filings — 5 × CORRESP, 5 × UPLOAD, 2 × DRS/A and 12 other forms
Counted, not listed; the year is on EDGAR.
2022 · 1 filing — 1 × DRS
Counted, not listed; the year is on EDGAR.
About this data#
Abivax SA American Depositary Shares (ABVX) has 105 filings on EDGAR going back to 2022: 3 annual reports, 0 quarterly reports and 36 current reports, plus proxy statements, insider forms and ownership schedules. Its latest annual report, a 20-F, was filed on Mar 23, 2026 for the fiscal year ended Dec 31, 2025. The most recent 8-K, on Sep 21, 2026, covered a material event. Not investment advice.
Every row is a filing EDGAR lists for the registrants that have been Abivax SA American Depositary Shares, read from the SEC’s submissions index each morning; a filing accepted after that read appears the next day. Where a company changed its filing entity (a holding-company reorganisation, Google into Alphabet) the predecessor’s filings are shown for the years it filed as the company, derived from the filings themselves. Dates are the filing date; the period is the report’s own. The latest 3 years of reports are listed in full, the next years to 10 without their 8-Ks, and older years are counted; the other forms are counted too, with the newest 25 of each of the latest 3 years shown. Insider transactions are the Form 4 and Form 5 documents themselves, filed since January 2026, every number as the insider filed it: a day’s lots are summed, a blank price adds its shares and no dollars, and a purchase through an employee stock plan is a plan purchase, not insider buying. An 8-K’s headline is the first line of the press release it furnishes (Exhibit 99), read from the filing and shown word for word; where two independent readings of the exhibit do not agree, the 8-K is described by its items instead. The documents stay on sec.gov, public domain, and every link opens the SEC’s copy. ChartRow does not summarise or interpret filings.
FAQ#
- Where can I read ABVX's latest 10-K?
- ABVX's latest annual report, a 20-F, was filed on Mar 23, 2026 for the fiscal year ended Dec 31, 2025. It is linked above and opens on EDGAR, the SEC's own site, where every exhibit is also listed.
- When did ABVX last file an 8-K?
- On Sep 21, 2026 it filed a current report. An 8-K reports a material event between quarterly reports; the one that furnishes the quarter's results is filed under Item 2.02.
- How many SEC filings has ABVX made?
- 105 filings are on EDGAR under the registrant records that have been Abivax SA American Depositary Shares, going back to 2022; 2 of them are insider ownership forms (Forms 3, 4, 5 and 144).